News & Updates
Filter by Specialty:
Finerenone shields against pneumonia, COVID-19 in diabetic patients with CKD
Patients with concomitant chronic kidney disease (CKD) and type 2 diabetes (T2D) who are undergoing mineralocorticoid receptor blockade with finerenone are better protected against pneumonia and COVID-19, according to a secondary analysis of data from the FIDELITY trials.
Finerenone shields against pneumonia, COVID-19 in diabetic patients with CKD
02 Nov 2022
Carbapenem-sparing cephamycins effective in E coli-induced UTI
Cefmetazole and cefoxitin prove to be effective in the treatment of patients with urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli, according to two separate studies presented at IDWeek 2022.
Carbapenem-sparing cephamycins effective in E coli-induced UTI
28 Oct 2022
COVID-19 worsens antibiotic resistance
While rare, infection with antibiotic-resistant gram-negative bacteria (AR-GNB) following a positive COVID-19 diagnosis is more severe and often results in worse outcomes, according to a study presented at the recent Virtual ID Week 2022.
COVID-19 worsens antibiotic resistance
28 Oct 2022
B/F/TAF safe, effective in adults with high HIV-1 RNA, low CD4 count
Adults with a high baseline HIV-1 RNA or low CD4 count may benefit from initial treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), which has been shown to be safe and efficacious over 5 years of follow-up in a study presented at the ID Week 2022 Virtual Conference.
B/F/TAF safe, effective in adults with high HIV-1 RNA, low CD4 count
27 Oct 2022
Ridinilazole triggers clinical response in CDI, inhibits recurrence
In patients with Clostridioides difficile infections (CDI), treatment with ridinilazole (RDZ) leads to high and sustained rates of clinical response, according to a study presented at the recently concluded Virtual ID Week 2022. Compared with vancomycin (VAN), RDZ also more strongly prevents recurrent CDI (rCDI).
Ridinilazole triggers clinical response in CDI, inhibits recurrence
27 Oct 2022
COVID-19 oral antivirals reduce in-hospital mortality and healthcare utilization in real-world setting
Use of molnupiravir or nirmatrelvir/ritonavir in high-risk patients with mild-to-moderate COVID-19 is associated with reduced in-hospital mortality, reduced hospital admissions or readmissions, and potential healthcare cost savings, according to a real-world retrospective cohort study led by researchers from the Chinese University of Hong Kong and the University of Hong Kong.
